Investing.com -- Nuwellis Inc (NASDAQ: NUWE ) stock jumped 15% after the medical technology company announced it has been granted a new U.S. patent for its fluid management technology.

The company, which focuses on fluid management solutions, received U.S. Patent No. 12,357,734 titled "Extracorporeal Blood Filtering Machine and Methods" on July 15, 2025. The patent covers methods for improving the accuracy of fluid balance calculations in continuous renal replacement therapy (CRRT) systems.

The newly patented technology addresses a significant issue in CRRT systems that use weight-based measurements. While most systems assume a default fluid density of 1 g/mL, actual fluid densities vary, potentially leading to clinically relevant fluid balance errors if left uncorrected. Nuwellis’ approach enables systems to account for density through user input, machine measurement, or derived data.

"Expanding our intellectual property portfolio is a key part of our strategy," said John Erb, Chief Executive Officer of Nuwellis. "Each new patent reinforces our commitment to building long-term value through innovation that supports patients, clinicians, and our future growth."

The patent joins Nuwellis’ growing portfolio of pending U.S. patents related to its proprietary system and methods, strengthening the company’s position in the extracorporeal fluid management field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.